Search research articles
Contact Us
Filters
Showing results (261-270 of 271) with videos related to
Page
of 28
Sort By:
Cancer Research
|
September 2, 2018
HER2/EGFR-AKT Signaling Switches TGFβ from Inhibiting Cell Proliferation to Promoting Cell Migration in Breast Cancer
Fei Huang, Qiaoni Shi, Yuzhen Li, et al.
Blood Advances
|
January 4, 2018
Osteomacs interact with megakaryocytes and osteoblasts to regulate murine hematopoietic stem cell function
Safa F Mohamad, Linlin Xu, Joydeep Ghosh, et al.
Plant Physiology
|
December 3, 2025
CsNAC2 and CsMYB306 orchestrate a jasmonate signaling cascade contributing to tea plant resistance to Ectropis obliqua
Jiaxing Li, Mei Li, Honglian Gu, et al.
Frontiers in Pharmacology
|
December 26, 2022
3CLpro inhibitors: DEL-based molecular generation
Feng Xiong, Honggui Xu, Mingao Yu, et al.
Emerging Microbes & Infections
|
October 13, 2022
Omicron infections profile and vaccination status among 1881 liver transplant recipients: a multi-centre retrospective cohort
Ensi Ma, Jingwen Ai, Yi Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 31, 2025
Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/<i>TP53</i> Mutation: SEQUOIA Arm D Results
Mazyar Shadman, Talha Munir, Shuo Ma, et al.
Blood Advances
|
August 19, 2025
Zanubrutinib in the treatment of patients with del(17p) and/or TP53 CLL/SLL: analysis across clinical studies
Constantine S Tam, Mary Ann Anderson, Martin Simkovic, et al.
Haematologica
|
January 25, 2024
Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies
Linlin Xu, Mazyar Shadman, Ian W Flinn, et al.
The Lancet. Haematology
|
November 18, 2022
Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study
Mazyar Shadman, Ian W Flinn, Moshe Y Levy, et al.
Haematologica
|
August 19, 2017
Erythropoietin stimulates murine and human fibroblast growth factor-23, revealing novel roles for bone and bone marrow
Erica L Clinkenbeard, Mark R Hanudel, Keith R Stayrook, et al.
Page
of 28
Search research articles
Search
Showing results (261-270 of 271) with videos related to
Sort By:
Page
of 28
Cancer Research
|
September 2, 2018
HER2/EGFR-AKT Signaling Switches TGFβ from Inhibiting Cell Proliferation to Promoting Cell Migration in Breast Cancer
Fei Huang, Qiaoni Shi, Yuzhen Li, et al.
Blood Advances
|
January 4, 2018
Osteomacs interact with megakaryocytes and osteoblasts to regulate murine hematopoietic stem cell function
Safa F Mohamad, Linlin Xu, Joydeep Ghosh, et al.
Plant Physiology
|
December 3, 2025
CsNAC2 and CsMYB306 orchestrate a jasmonate signaling cascade contributing to tea plant resistance to Ectropis obliqua
Jiaxing Li, Mei Li, Honglian Gu, et al.
Frontiers in Pharmacology
|
December 26, 2022
3CLpro inhibitors: DEL-based molecular generation
Feng Xiong, Honggui Xu, Mingao Yu, et al.
Emerging Microbes & Infections
|
October 13, 2022
Omicron infections profile and vaccination status among 1881 liver transplant recipients: a multi-centre retrospective cohort
Ensi Ma, Jingwen Ai, Yi Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 31, 2025
Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/<i>TP53</i> Mutation: SEQUOIA Arm D Results
Mazyar Shadman, Talha Munir, Shuo Ma, et al.
Blood Advances
|
August 19, 2025
Zanubrutinib in the treatment of patients with del(17p) and/or TP53 CLL/SLL: analysis across clinical studies
Constantine S Tam, Mary Ann Anderson, Martin Simkovic, et al.
Haematologica
|
January 25, 2024
Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies
Linlin Xu, Mazyar Shadman, Ian W Flinn, et al.
The Lancet. Haematology
|
November 18, 2022
Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study
Mazyar Shadman, Ian W Flinn, Moshe Y Levy, et al.
Haematologica
|
August 19, 2017
Erythropoietin stimulates murine and human fibroblast growth factor-23, revealing novel roles for bone and bone marrow
Erica L Clinkenbeard, Mark R Hanudel, Keith R Stayrook, et al.
Page
of 28